TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia Secondary to Nephrotic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
PROTOCOL ENTRY CRITERIA:~--Disease Characteristics--~Chronic hyperlipidemia with treatment-resistant nephrotic syndrome; Must have received at least 2 months of therapy with steroids on a daily or alternate basis~Primary nephropathy described as minimal change nephrotic syndrome, mesangioproliferative glomerulonephritis, IgM neuropathy, and focal segmental glomerulosclerosis~Glomerular filtration rate at least 30 mL/min~LDL cholesterol at least 160 mg/dL~--Prior/Concurrent Therapy--~No concurrent medications affecting or interacting with lipids or atorvastatin, with the exception of angiotensin converting enzyme inhibitors at discretion of referring physician, including: lipid-lowering medications, beta blockers, thiazides, fish oils, cyclosporine, Cytoxan, azathioprine, chlorambucil, and erythromycin~Concurrent prednisone and other corticosteroids allowed on a continual basis at a dose of no greater than 1 mg/kg every other day (maximum dose, no greater than 40 mg every other day); Concurrent acute courses of steroids no greater than 1 week for other unrelated conditions (e.g., asthma) also allowed~--Patient Characteristics--~Hepatic: ALT or AST less than 2 times normal~Renal: See Disease Characteristics; Creatine phosphokinase less than 3 times normal~Other: No history of familial hypercholesterolemia; No systemic disease such as systemic lupus, Schoenlein-Henoch purpura, Hodgkin's disease, polyarteritis nodosum, sickle cell disease, or HIV; Not pregnant; Effective contraception required of all adolescent patients

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Female 18-65 years of age (inclusive)~2. Diagnosed with IBS based on the following criteria (Rome III criteria):~   * Symptom onset at least 6 months prior to diagnosis, and~  * Recurrent abdominal pain or discomfort at least 3 days per month for the past 3 months, and~  * Abdominal discomfort or pain associated with two or more of the following at least 25% of the time:~  * improvement with defecation~  * onset associated with a change in frequency of stool/defecation~  * onset associated with a change in form (appearance) of stool~3. Diagnosed with IBS-D, defined as loose/watery stools ≥ 25% and hard/lumpy stools ≤ 25% of defecations~Exclusion Criteria:~* Any structural abnormality of the gastrointestinal (GI) tract (other than esophagitis or gastritis)~* History of Chron's disease, ulcerative colitis, diabetes mellitus, lactose malabsorption, malabsorption syndromes, celiac sprue, or any upper GI symptoms that may impact the assessment of IBS symptoms

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Experimental Arm 1 (Type: EXPERIMENTAL): ONO-2952 Active tablets, every day for 2 weeks
- Placebo Arm (Type: PLACEBO_COMPARATOR): ONO-2952 Matching Placebo every day for 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Creon Use in Coeliac Patients With Low Faecal Pancreatic Elastase

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with coeliac disease and having chronic diarrhoea (\>3 loose/ liquid motions a day for more than 4 weeks)~* Patients with a low faecal elastase (\<200 ug/g),~* Patients aged 16 years or over~* Patient able to give written consent to participate~* Patient not currently on Creon~Exclusion Criteria:~* Patients with normal faecal elastase (\> 201ug/g),~* Patients under the age of 16~* Patients allergic to pork or any pig product (advice from the drug manufacturer)~* Patients that are pregnant or are breast-feeding~* Patients taking alternative medication that could affect bowel frequency~* Where an alternative diagnosis for the chronic diarrhoea is established, these patients will be excluded from the trial~* Patients who are unable to speak or understand English

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Active treatment will be 2 capsules of Creon 25,000 units three times per day and the placebo will be 2 capsules three times per day; for 6 weeks treatment overall.
- Creon (Type: ACTIVE_COMPARATOR): Active treatment will be 2 capsules of Creon 25,000 units three times per day and the placebo will be 2 capsules three times per day; for 6 weeks treatment overall.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Inpatient Clinical Trial of NAC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female between the ages of 18 and 80 years of age at Visit 1~2. Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.~3. Able to perform reproducible spirometry according to ATS criteria~4. Physiological evidence of airflow obstruction (FEV1 bronchodilator reversibility of ≥ 12% or hyperreactivity to methacholine reflected by a methacholine PC20 ≤ 16 mg/mL)~5. Clinical history of asthma per patient report or medical record~6. Pre-bronchodilator FEV1 \> 35% predicted~7. Post-bronchodilator FEV1 \> 40% but \< 90% predicted~8. Asthma requiring treatment with inhaled corticosteroids (ICS) for 3 months or greater~9. CT mucus score \> 3~Exclusion Criteria:~1. Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.~2. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.~3. Smoking of tobacco or other recreational inhalants in last year and/or \>10 pack-year smoking history~4. Current participation in an investigational drug trial~5. Other chronic pulmonary disorders, including (but not limited to) cystic fibrosis, chronic obstructive pulmonary disease, chronic bronchitis, vocal cord dysfunction (that is the sole cause of respiratory symptoms and at the PI's discretion), severe scoliosis or chest wall deformities that affect lung function, or congenital disorders of the lungs or airways~6. Unwillingness to follow study procedures~7. History of allergy or intolerance to study drug~8. Any other criteria that places the subject at unnecessary risk according to the judgment of the Principal Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- N-acetylcysteine (Type: EXPERIMENTAL): This study will look at the effects of a medication, called n-acetylcysteine or NAC, on lung function. NAC is already approved for use in people with chronic airway conditions, including asthma. However, it is not known who this medication works best in. We believe this medication will likely have the most benefit in people with asthma that have mucus in their airways or mucus plugging. Initial study procedures will include lung function measurements, a low dose CT scan, a blood draw, and a sputum induction. The CT lung imaging will identify asthmatics with mucus plugs.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Prone Positioning in Awake Patients With COVID-19 Requiring Hospitalization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (age ≥ 18 years)~* Suspected or Confirmed COVID-19 (Suspected: High clinical suspicion AND pending COVID-19 assay; Confirmed: Positive COVID-19 assay within 10 days)~* Scheduled for admission or already admitted to an inpatient hospital bed~* Patients must be enrolled within 48 hours of hospital admission~Exclusion Criteria:~* Pregnant~* Prisoner~* Contraindication to prone positioning: known increased intracranial pressure \>30 mm Hg or cerebral perfusion pressure \<60 mm Hg, increased abdominal pressure or risk for abdominal compartment syndrome, massive hemoptysis requiring urgent intervention, tracheal surgery or sternotomy during previous 14 days, facial surgery or serious facial trauma within 14 days, pacemaker implantation within 48 hours, unstable spine, femur, or pelvic fractures, chest tube, mean arterial pressure less than 65 mm Hg~* Lung transplant~* Burns on more than 20% of body surface~* Chronic respiratory failure requiring: mechanical ventilation via endotracheal device (e.g. tracheostomy tube, orotracheal tube, or nasotracheal tube)~* Inability to change position from supine to prone and prone to supine without assistance~* Receiving end of life care, comfort measures only, or hospice

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prone Positioning (Type: EXPERIMENTAL): None
- Usual care (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of Constraint-induced Therapy Combined With Visual-spatial Cueing Strategy in Patients With Acute Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized patient in neurovascular unit for stroke~* Time since stroke between 2 and 4 days~* Movement capacity of the upper arm (against gravity) :~* Ability to extend actively the metacarpophalangeal and interphalangeal joints at least 10°, and the wrist 20°~* Ability to bend actively the elbow at least 45°~* Ability to bend and abduct actively the shoulder at least ≥ 45°~* Age ≥ 18 years old~* Patient agreement to join the study~* Patient covered by french social security~Exclusion Criteria:~* Excessive spasticity : score \> 2 on the modified Ashworth scale~* Excessive pain in the affected arm : score ≥ 4 on the visual analogue scale~* Joint limitation on the affected arm~* Patient under guardianship or curatorship~* Pregnant or breastfeeding woman

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Constraint-induced movement therapy (Type: EXPERIMENTAL): Patient's unaffected arm is restrained, by a glove including thumb, during activities of daily life (bathing, grooming, dressing and feeding = approx. 4h/day).~Visual spatial cueing is displayed in the bedroom and the bathroom.
- Usual care (Type: NO_INTERVENTION): Usual care of the neurovascular unit. = No constraint, no cueing, and same physiotherapy intervention as experimental arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Low Pain Prediction in Cesarean Section Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* anticipated pain level estimated to be in the lowest 20th percentile (calculated \<34.3 utilizing our standard preoperative questionnaire)~* age \>/= 18~* not allergic to any study medications to be utilized in this study~* singleton pregnancy~Exclusion Criteria:~* allergies to morphine or acetaminophen~* diagnosis of a chronic pain disorder~* weight \>300 lbs~* hepatic disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- duramorph (Type: ACTIVE_COMPARATOR): duramorph 150 mcg administered spinally with placebo capsules administered by mouth every 6 hours x 4 doses during first 24 hours
- no duramorph (Type: EXPERIMENTAL): no duramorph is administered spinally for surgery; subjects receive acetaminophen 1 G orally x 4 doses during first 24 hours postoperatively

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: High Flow Oxygen in Patients Undergoing Suspension Laryngoscopy Under General Anesthesia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Consent for participation~* Affiliation to the french social security system~* Patients undergoing any suspension laryngoscopy other than laser surgery and cavoscopy and expected to last less than 30 minutes~Exclusion Criteria:~* Pregnancy~* Epilepsy~* Arrhythmia~* Pulmonary hypertension~* Lung disease with basal SpO2\<95%~* Obstructive laryngeal tumor~* BMI\>30kg.m-2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High Flow Apneic Oxygenation (Type: EXPERIMENTAL): Apneic oxygenation using Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Infantile Colic: Study of the Efficacy of Lactobacillus GG (ATCC 53103) Plus Chamomile in Breastfeeding Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Caregiver is able to give written informed assent and willingness to participate in the study and comply with its procedures~* Male or Female~* Born at term (38-41 weeks gestation)~* Aged 3 wks-16 wks~* Be in generally good health as determined by the investigators~* BMI between 5th and 95th percentiles~* Exclusively breastfeeding throughout the study~* Be willing to complete crying diary~* Be willing to administer the probiotic as prescribed~* Be willing to completed the Quality of Life instrument before and after the intervention~* Meets the Rome criteria for colic~Exclusion Criteria:~* Are less than 3 weeks or greater than 17 weeks of age or older~* Underweighted or obese based on BMI. Less than 5th or greater than 95th percentiles~* Mothers on an exclusively vegan diet and those with a chronic disease requiring medication therapy~* Mothers or infants having a significant acute or chronic existing illness \[cardiovascular, gastrointestinal, immunological\] or a condition, which in the investigators judgment contraindicates involvement in the study~* Mothers or infants having a condition or taking a medication, dietary supplement or food product that the investigator believes would interfere with the objectives of the study pose a safety risk or confound the interpretation of the study results~* Individuals who, in the opinion of the investigator, are considered to be poor clinical attendees or unlikely for any reason to be able to comply with the trial~* Mothers or infants who are receiving treatment involving experimental drugs~* Participation in a recent experimental trial less than 30 days prior to this study~* Inability to complete the diary, survey scales and appointments~* First degree relative allergic to ragweed, asters, or chrysanthemums~* The following concomitant medications are not allowed at any time during or 1 week prior to initiation of the study: antibiotics or probiotics

- Gender: ALL
- Minimum Age: 3 Weeks
- Maximum Age: 16 Weeks
- Healthy Volunteers: f

Study Arms:
- chamomile/probiotic arm (Type: EXPERIMENTAL): Infant will receive 5 drops of the study product once per day with a feeding at midday.
- Placebo of chamomile/probiotic arm (Type: PLACEBO_COMPARATOR): Infant will receive 5 drops of a placebo product once a day at midday.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient must have given his/her informed and signed consent~* The patient must be insured or beneficiary of a health insurance plan~* The patient is available for 12 months of follow-up~* The patient is a candidate for total thyroidectomy because of a nodular pathology, a diffuse goiter, thyroiditis, or Basedow's disease~* Patient has calcitoninemia \< 9 ng/pl~* Patient has normal calcemia~* Patient has PTH level between 5 ng/l and 75 ng/l~* The subject has a normal laryngeal mobility~Exclusion Criteria:~* The patient is participating in another study~* The patient is in an exclusion period determined by a previous study~* The patient is under judicial protection, under tutorship or curatorship~* The patient refuses to sign the consent~* It is impossible to correctly inform the patient~* The patient is pregnant~* The patient is breastfeeding~* The patient is not available for 12 months of follow-up~* Subject has a preoperative diagnosis of cancer on fine needle aspiration biopsy of the thyroid or cervical lymph node~* Lymph node metastasis strongly suspected clinically and/or sonographically~* The subject has an extension of substernal thyroid (diving goiter)~* Family history of medullary thyroid cancer~* The subject has a history of neck surgery~* Contraindication for general anesthesia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Robot arm (Type: EXPERIMENTAL): Patients in this arm will have a thyroidectomy performed using a robot-assisted endoscopic technique.
- Open surgery (Type: ACTIVE_COMPARATOR): Patients in this arm will have a thyroidectomy using an open surgical technique.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Feasibility Study on the Use of F-18-FDG-PET and Optical Imaging in Evaluation of Radiation-induced Oral Mucositis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Non-operated histologically confirmed squamous cell carcinoma of the oral cavity, oropharynx (except the posterior wall) and lymph node metastases from the unknown primary tumor (CUP)~* Stage T1-4; Tx N+ for the CUP~* Multidisciplinary Group of Head and Neck Tumors at Ghent University Hospital decision of radical radiotherapy (±concurrent chemotherapy)~* Informed consent obtained, signed and dated before specific protocol procedures.~Exclusion Criteria:~* Age \< 18 years~* Pregnant or lactating women~* Active infection or fistula in the oral/oropharyngeal mucosa~* Previous cancer of the oral cavity and the oropharynx~* Prior head-and-neck radiotherapy~* Expectation of non-compliance with the study protocol~* Known allergy for topical anesthetics (Xylocaïne)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues